| Outcome Measures: |
Primary: the change in urinary protein-creatinine ratio from baseline to the end of 12 weeks, Change in urinary protein excretion, determined as urinary Protein-creatinine ratio compared to baseline, after 12 weeks of treatment, 12 weeks | Secondary: the change in urinary albumin-creatinine ratio from baseline to the end of study, Change in urinary albumin excretion, determined as urinary albumin-creatinine ratio compared to baseline, after 12 weeks of treatment, 12 weeks|the proportion of patients wifh more than 50% decrease of urinary protein-creatinine ratio, number of patients with wifh more than 50% decrease of urinary protein-creatinine ratio compared to baseline, after 12 weeks of treatment, 12 weeks|the change in urinary beta2-microglobulin-creatinine ratio from baseline to the end of study, Change in urinary beta2-microglobulin--creatinine ratio compared to baseline, after 12 weeks of treatment, 12 weeks|the change in urinary NAG-creatinine ratio from baseline to the end of study, Change in urinary NAG-creatinine ratio compared to baseline, after 12 weeks of treatment, 12 weeks
|
